
QUICK LINKS
c-Myc Antibody (C-8) is a mouse monoclonal IgG2a kappa light chain antibody raised against the full-length human c-Myc. Anti-c-Myc monoclonal antibody (C-8) recognizes an epitope within the c-Myc protein from mouse, rat, and human sources. c-Myc mouse monoclonal antibody (C-8) demonstrates effectiveness in Western blotting, immunoprecipitation, immunofluorescence, and ELISA applications. c-Myc (C-8) antibody is available in non-conjugated form and multiple conjugated forms including agarose, HRP, PE, FITC, and various Alexa Fluor® conjugates, offering flexibility for diverse assay requirements. The c-Myc protein, encoded by the MYC proto-oncogene on chromosome 8q24, is a nuclear phosphoprotein that functions as a transcription factor regulating genes involved in cell cycle progression, apoptosis, and cellular transformation. c-Myc contains several conserved domains, including the basic helix-loop-helix leucine zipper (bHLH-LZ) domain at the C-terminus, essential for DNA binding and heterodimerization with Max protein. The c-Myc/Max complex binds specific E-box DNA sequences (CACGTG) in target gene promoters to regulate their transcription. Overexpression or amplification of the c-Myc gene is a hallmark of many human cancers, such as Burkitt′s lymphoma, neuroblastoma, and carcinomas of the lung, breast, colon, and cervix, leading to uncontrolled cell proliferation and inhibition of differentiation. Under certain conditions, c-Myc can also induce apoptosis, acting as a fail-safe mechanism against tumorigenesis, although this pathway can be bypassed in the presence of additional oncogenic signals or loss of tumor suppressor functions. Post-translational modifications of c-Myc, such as phosphorylation at specific residues, modulate c-Myc stability and activity; for example, phosphorylation at Ser62 stabilizes c-Myc, while subsequent phosphorylation at Thr58 targets c-Myc for degradation via the ubiquitin-proteasome pathway. Mutations affecting these regulatory sites can enhance the oncogenic potential of c-Myc. Given c-Myc′s central role in cell biology and cancer, c-Myc remains a critical target in cancer research and therapeutics. c-Myc monoclonal antibody (C-8) serves as an indispensable tool for researchers investigating the expression, regulation, and function of c-Myc in normal and diseased states, facilitating studies aimed at understanding oncogenesis mechanisms and developing novel anti-cancer strategies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Myc Antibody (C-8) | sc-41 | 200 µg/ml | $316.00 | |||
Myc Antibody (C-8): m-IgG Fc BP-HRP Bundle | sc-525417 | 200 µg Ab; 10 µg BP | $354.00 | |||
Myc Antibody (C-8): m-IgG2a BP-HRP Bundle | sc-546242 | 200 µg Ab; 10 µg BP | $354.00 | |||
Myc Antibody (C-8) X | sc-41 X | 200 µg/0.1 ml | $316.00 | |||
Myc Antibody (C-8) AC | sc-41 AC | 500 µg/ml, 25% agarose | $416.00 | |||
Myc Antibody (C-8) HRP | sc-41 HRP | 200 µg/ml | $316.00 | |||
Myc Antibody (C-8) FITC | sc-41 FITC | 200 µg/ml | $330.00 | |||
Myc Antibody (C-8) PE | sc-41 PE | 200 µg/ml | $343.00 | |||
Myc Antibody (C-8) Alexa Fluor® 488 | sc-41 AF488 | 200 µg/ml | $357.00 | |||
Myc Antibody (C-8) Alexa Fluor® 546 | sc-41 AF546 | 200 µg/ml | $357.00 | |||
Myc Antibody (C-8) Alexa Fluor® 594 | sc-41 AF594 | 200 µg/ml | $357.00 | |||
Myc Antibody (C-8) Alexa Fluor® 647 | sc-41 AF647 | 200 µg/ml | $357.00 | |||
Myc Antibody (C-8) Alexa Fluor® 680 | sc-41 AF680 | 200 µg/ml | $357.00 | |||
Myc Antibody (C-8) Alexa Fluor® 790 | sc-41 AF790 | 200 µg/ml | $357.00 |